06.11.2023 - - Collaborative project between Pacific Blue Cross and HealthTech Connex designed to reduce long-term disability and improve quality of life for individuals suffering from traumatic brain injury (“TBI”) 56% of study participants who were . Seite 1
“Despite its availability in Canada, there remains limited research on the use and efficacy of medical cannabis in PTSD patients,” said Rowena Rizzotti, vice president of healthcare and innovations and project lead for Legion Veterans Village, in a statement.
“We are pleased to partner with and leverage Knowde Group’s research expertise and insight to pursue potential treatment options for PTSD for our veterans and first responders.”
Construction on the $312 million Legions Veterans Village at 13525 106 Avenue, replacing Whalley Legion Branch 229, commenced in May 2019.
Construction progress at Legion Veterans Village at 13525 106 Avenue, Surrey, as of early February 2021. (Legion Veterans Village)
The first phase under construction features a 29-storey tower with an architectural form taking the inspiration of the Canadian National Vimy Memorial in France. It contains the Centre of Excellence and the Innovation Centre for Rehabilitation, which includes clinical r
HealthTech Connex s Centre for Neurological Studies and the
NeuroCatch Platform (Surrey), the
Woodview Autism and Mental Health Services (Ontario). This partnership initiative emerged from Surrey s
Health and Technology District and is a product of decades of leading-edge research started by Dr. Catherine Mateer and Dr. Kimberly Kerns from the University of Victoria. It represents a major milestone in translating leading research into health technology benefits for Canadians and children around the globe.
Through a combination of research, clinical studies, innovation, and clinical expertise, the multi-year partnership enables collaborators to offer a video-game based treatment program for children with neurodevelopmental disabilities. Their goal is to help children with special needs reach their potential through the development and use of novel, evidence-based innovations, to improve neuro-behavioural outcomes in children with neurodevelopmental challenges.
Havn Life Sciences Inc.: Havn Life Announces Strategic Clinical Trial Partnership with HealthTech Connex Inc.
VANCOUVER, BC / ACCESSWIRE / February 2, 2021 / Havn Life Sciences Inc. (CSE:
HAVN
5NP
) (the Company or Havn Life ), a biotechnology company pursuing standardized extraction of psychoactive compounds and the development of natural healthcare products, is pleased to announce a strategic partnership with neuroscience and technology leader, HealthTech Connex Inc.
Upon approval of the Company s Licensed Dealer application, the Company s subsidiary, Havn Labs, will be a preferred psychedelic supply partner for future clinical trials launched by HealthTech Connex s Centre for Neurology Studies. In addition, HealthTech Connex will promote Havn Life s library of naturally derived compounds to its other clinical trial partners and be a preferred partner for the execution of Havn Life clinical trials.
Havn Life Announces Strategic Clinical Trial Partnership with HealthTech Connex Inc saltlakecitysun.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from saltlakecitysun.com Daily Mail and Mail on Sunday newspapers.